We suggest that ClinVar should be used with caution as a resource to determine if a BARD1 variant may play a role in hereditary cancer risk, as few of these variants have been vetted by expert review panels akin to those available for variants in BRCA1 and BRCA2 (www.brcaexchange.org) [142]. The gene discussed is BARD1; the disease is hereditary cancer.